Retinoblastoma protein promotes oxidative phosphorylation through upregulation of glycolytic genes in oncogene-induced senescent cells

Shin-ichiro Takebayashi,^{1,2}* Hiroshi Tanaka,¹ Shinjiro Hino,¹ Yuko Nakatsu,¹ Tomoka Igata,¹ Akihisa Sakamoto,¹ Masashi Narita³ and Mitsuyoshi Nakao^{1,2,4}

¹Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

²Program for Leading Graduate Schools 'HIGO (Health life science: Interdisciplinary and Glocal Oriented) Program', Kumamoto University, Kumamoto, Japan

³Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK

⁴Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan

Summary

Metabolism is closely linked with cellular state and biological processes, but the mechanisms controlling metabolic properties in different contexts remain unclear. Cellular senescence is an irreversible growth arrest induced by various stresses, which exhibits active secretory and metabolic phenotypes. Here, we show that retinoblastoma protein (RB) plays a critical role in promoting the metabolic flow by activating both glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) in cells that have undergone oncogene-induced senescence (OIS). A combination of real-time metabolic monitoring, and metabolome and gene expression analyses showed that OIS-induced fibroblasts developed an accelerated metabolic flow. The loss of RB downregulated a series of glycolytic genes and simultaneously reduced metabolites produced from the glycolytic pathway, indicating that RB upregulates glycolytic genes in OIS cells. Importantly, both mitochondrial OXPHOS and glycolytic activities were abolished in RB-depleted or downstream glycolytic enzyme-depleted OIS cells, suggesting that RB-mediated glycolytic activation induces a metabolic flux into the OXPHOS pathway. Collectively, our findings reveal that RB essentially functions in metabolic remodeling and the maintenance of the active energy production in OIS cells.

Key words: gene regulation; glycolysis; metabolic remodeling; oncogene-induced senescence; oxidative phosphorylation; retinoblastoma protein.

Agina C

Mitsuyoshi Nakao, Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan. Tel.: +81 96 373 6800; fax: +81 96 373 6804; e-mail: mnakao@gpo.kumamoto-u.ac.jp

The accession number of the microarray data in GEO is GSE60652.

*Present address: Department of Biochemistry and Proteomics, Graduate School of Medicine, Mie University, Mie, Japan

Accepted for publication 6 April 2015

Introduction

Cellular senescence is a state of essentially irreversible growth arrest that is induced by various stresses, such as shortened telomeres, DNA damage, and oncogene activation. It is thought to function as an exclusion of unnecessary cells or as an anticancer mechanism. Senescent cells usually exhibit morphological features including an enlarged size, flattened shape, increased β -galactosidase activity, a senescence-associated secretory phenotype, and the formation of senescence-associated heterochromatin foci (SAHF) (Campisi & d'Adda di Fagagna, 2007; Kuilman *et al.*, 2010; Rodier & Campisi, 2011; Lopez-Otin *et al.*, 2013; Munoz-Espin & Serrano, 2014; Perez-Mancera *et al.*, 2014; Salama *et al.*, 2014). Senescent cells also possess some dynamic functions that together make up the metabolically active phenotype.

Several signaling pathways that activate the senescence program have been identified in vitro, and a deficiency of these pathways is often found in tumors in vivo (Collado & Serrano, 2010), suggesting that bypassing cellular senescence could lead to tumorigenesis. Among such pathways, the retinoblastoma protein (RB) has been shown to play a pivotal role in the transcriptional repression of cell cycle genes in both oncogene-induced senescence (OIS) and replicative senescence (RS) (Ben-Porath & Weinberg, 2005). In senescent cells, RB represses E2F target genes including cell cycle regulators (Narita et al., 2003), and this repression is partly caused by the RB-mediated recruitment of transcriptional repressors such as histone deacetylases to the regulatory sites of its target genes (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998). Interestingly, RB is required for SAHF formation through cooperation with histone chaperone proteins HIRA and antisilencing function 1A (Narita et al., 2003; Ye et al., 2007). RB is also known to act as a transcriptional activator in some contexts (Talluri & Dick, 2012), although it remains unclear whether RB-mediated transcriptional activation contributes to senescent phenotypes. Thus, RB is likely to orchestrate several senescence-associated phenomena and to contribute to the stable maintenance of the senescence program.

Cellular metabolism produces energy and the materials required for cell structure and function, and its regulation is necessary to meet the energy demands of the cellular state. To generate ATP as a cellular fuel, normal cells mainly use OXPHOS in the presence of oxygen and anaerobic glycolysis in its absence. However, proliferative and cancer cells typically show a bias toward aerobic glycolysis even in the presence of oxygen because of their high energy demand for rapid growth. Recently, the metabolic profiling of mouse embryonic stem cells (ESCs), mouse epiblast stem cells (EpiSC), and human embryonic stem cells (hESCs) found that EpiSCs/hESCs possess higher glycolytic and lower OXPHOS activities compared with ESCs (Zhou et al., 2012). Regulation of a set of mitochondrial IV COX genes was thought to be involved in this phenomenon. Human-induced pluripotent stem cells also displayed higher glycolytic rates relative to the original somatic cells, similar to hESCs (Varum et al., 2011). Although it is still uncertain whether metabolic remodeling is a cause or consequence of cellular reprogramming, these studies clearly indicate that metabolic pathways can change depending on cellular states.

© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Correspondence

Recent studies have shown that cells undergoing OIS have higher OXPHOS activities compared with growing cells (Quijano et al., 2012; Dorr et al., 2013; Kaplon et al., 2013). However, the mechanisms determining the OIS-associated OXPHOS activation are poorly understood. RB is activated during cellular senescence induction and plays crucial roles in senescence-associated phenotypes (Narita et al., 2003; Ben-Porath & Weinberg, 2005). Given that RB has been shown to modulate mitochondrial activity through regulating metabolic gene expression (Takahashi et al., 2012), we examined the possibility that RB is involved in the OIS-associated OXPHOS activation in this study. Using oncogenic Ras-driven senescence in human fibroblasts, we show that RB is involved in increasing both glycolysis and OXPHOS activities in OIS cells. A combination of live metabolic monitoring, and metabolome and gene expression analyses revealed that the RB-dependent upregulation of metabolic genes at the RNA levels promotes glycolysis and subsequent OXPHOS activities. Our findings demonstrate a novel metabolic role for RB in OIS cells, suggesting that RB is a key molecule linking metabolic remodeling and cell cycle control in the senescent program.

Results

RB regulates metabolic remodeling during the induction of senescence

To characterize senescence-associated metabolic changes, we used an extracellular flux analyzer to assess the oxygen consumption rate (OCR), which mainly reflects the levels of mitochondrial OXPHOS activity, in human diploid fibroblasts IMR90 (growing) and the same cells undergoing OIS. OIS cells were prepared by 4-hydroxytamoxifen (4-OHT)-inducible Ras (H-*ras*V12) for 6 days as described previously (Hirosue *et al.*, 2012). OIS cells showed significantly higher basal OCRs compared with control growing cells (Fig. 1A, left), in agreement with previous reports (Quijano *et al.*, 2012; Dorr *et al.*, 2013; Kaplon *et al.*, 2013). Furthermore, as indicated by the vertical arrows in Fig. 1A, the maximum OXPHOS capacity was found to be dramatically increased in OIS cells following the addition of carbonyl cyanide-*p*-trifluoromethoxyphenylhydrazone (FCCP), the proton gradient discharger (Fig. 1A, right).

A comparable increase in the maximum OXPHOS capacity was found in RS cells that were prepared by repeated proliferation and free from Ras activation (Fig. 1B), indicating that senescent cells possess an increased mitochondrial OXPHOS activity. To test the involvement of the oncogenic signal, we removed Ras expression from already established OIS cells. Interestingly, OIS cells maintained higher levels of OXPHOS capacity even after a withdrawal of 4-OHT (Fig. 1C and Fig. S1A, +OHT/ –OHT). These results suggest that increased OXPHOS capacity in OIS cells does not result from a direct action of the oncogene.

Because RB has a significant function in cellular senescence and plays crucial roles in senescence-associated phenotypes (Narita *et al.*, 2003; Ben-Porath & Weinberg, 2005), we next examined whether it is involved in the mitochondrial OXPHOS capacity of OIS cells. To deplete the RB protein, cells were treated with a mixture of three small interfering RNAs (siRNAs) against *RB1* 2 days after Ras induction (Fig. 1D and Fig. S1B). RB knockdown of OIS (RB-KD OIS) reactivated genes encoding cell cycle progression proteins (*MCM3* and *MCM5*), and inflammatory cytokines (*IL6* and *IL8*) to a lesser extent, and moderately diminished the population of SAHF-positive cells (Fig. S1C,D). DNA replication, as measured by 5-ethynyl-2'-deoxyuridine (EdU) incorporation, was partially recovered in RB-KD OIS cells, probably from the

activation of certain checkpoint pathways (Fig. S1E) (Chicas *et al.*, 2010).

As expected, RB depletion by a mixture or individual siRNAs canceled the increase in OCR upon oncogene activation (Fig. 1E and Fig. S2A). To further clarify the RB function, RB-KD was performed in already established OIS cells (Fig. S2B). Under this RB-KD condition, the increased mitochondrial OXPHOS was also reversed, suggesting that the effect of RB-KD on OCR in OIS cells is not a consequence of incomplete senescence induction. Moreover, RB-KD similarly reversed the activation of the OXPHOS capacity in RS cells (Fig. S2C). Taken together, we concluded that RB is required for the activation of mitochondrial OXPHOS activity in senescent cells.

Metabolome profiling reveals the RB-dependent dynamics of cellular metabolites

To further understand RB-mediated metabolic remodeling in cellular senescence, we next carried out a metabolome analysis of each of three independent samples from growing IMR90, Ctrl-KD OIS, and RB-KD OIS cells (Fig. 2A and Table S1). We used capillary electrophoresis-time of flight mass spectrometry/triple quadrupole mass spectrometry (CE-TOFMS/QqQMS) to identify 103 metabolites in cellular metabolic pathways. Consistent with previous reports (Quijano et al., 2012; Kaplon et al., 2013), we detected increased levels of metabolites from glycolysis. the pentose phosphate pathway, and the tricarboxylic acid (TCA) cycle in Ctrl-KD OIS cells (Fig. 2B and Fig. S3). The increase in ATP in Ctrl-KD OIS cells is highly compatible with the activated metabolic flow (Fig. S3C). Notably, we found that RB depletion largely attenuated the OISassociated increase in the levels of these metabolites. Several metabolic intermediates in glycolysis (fructose 1,6-diphosphate, dihydroxyacetone phosphate, and glyceraldehyde 3-phosphate) showed a remarkable reduction in RB-KD OIS cells compared with Ctrl-KD OIS cells. This suggests that RB mediates activation of the glycolytic pathway, which may lead to the increased mitochondrial OXPHOS capacity.

To test RB-dependent glycolytic activation in OIS cells, we further measured the extracellular acidification rate (ECAR) under glucose starvation and subsequent addition, an index of glycolytic activity (Fig. 3A). The loss of RB in OIS cells decreased the ECAR compared with the OIS control. We then performed a kinetic analysis of glucose uptake, using 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-p-glucose (2-NBDG), a fluorescent glucose analog (Fig. 3B). The Ctrl-KD OIS cells showed a marked increase in glucose uptake compared with growing cells, while RB-KD OIS cells showed a similar uptake to Ctrl-KD OIS cells. This suggests that RB regulates the glycolytic pathway rather than glucose uptake.

RB upregulates glycolytic genes at the RNA levels in OIS cells

To examine how RB regulates metabolic gene expression, we performed genome-wide expression microarray analysis in growing, Ctrl-KD OIS, and RB-KD OIS cells. Gene set enrichment analysis (GSEA) using Kyoto Encyclopedia of Genes and Genomes gene sets was performed to identify RB-dependent biological pathways (Fig. 4A and Table S2). We found that the 'glycolysis and gluconeogenesis' gene set was uniquely upregulated in Ctrl-KD OIS but not RB-KD OIS cells, indicating that activation of the glucose metabolism pathway is RB-dependent in OIS cells. By contrast, some gene sets, such as 'cytokine and cytokine receptor interaction', were upregulated in both Ctrl-KD OIS and RB-KD OIS cells. This suggests that activation of the cytokine pathway is RB-independent.

Fig. 1 RB is required for increased mitochondrial OXPHOS activity in OIS cells. (A) Oxygen consumption rate (OCR) in growing and oncogene-induced senescence (OIS) cells. OIS was induced in IMR90 cells expressing oncogenic Ras (H-rasV12) following treatment with 4-hydroxytamoxifen (4-OHT) for 6 days. OCR was measured as the mitochondrial OXPHOS activity, using the extracellular flux analyzer (normalized to cell number). Respiratory chain inhibitors were added to the culture at the indicated time points. Values are means \pm SE of at least three technical replicates at each time point (see Experimental procedures for details). Data are representative of two independent experiments. Basal OCRs are shown by subtracting the rotenone-/antimvcintreated values from the initial values (prior to oligomycin addition) (left). Vertical arrows indicate the maximum OXPHOS capacity determined as the difference between the FCCP- and rotenone-/ antimycin-treated OCR values. (B) OCR in growing and replicative senescence (RS) cells. (C) The effect of oncogenic Ras removal on OCR in established OIS cells. OIS cells were established in the presence of 4-OHT for 6 days and further cultured in the presence (+OHT/+OHT) or absence of 4-OHT (+OHT/-OHT) for 4 days (Fig. S1A) (D) RNA interference-mediated knockdown of RB (RB-KD). Control siRNA or siRNAs against RB1 were introduced to OIS-inducing IMR90 cells (Fig. S1B). (E) The effect of RB-KD on OCR in OIS cells.



To further elucidate the RB-mediated transcriptional regulation of metabolic genes, we performed a K-means clustering of the 14 042 genes on the microarrays. This analysis revealed 20 gene clusters with distinct patterns of up- and downregulation in each cell state (Fig. 4B). Cluster 20 contained a set of genes that were upregulated in Ctrl-KD OIS cells but downregulated in RB-KD OIS cells (Fig. 4C). Based on gene ontology (GO) analysis, 307 of the 1748 genes in this cluster were involved in cellular metabolic processes (Table S3). Reverse transcription (RT)-PCR of glycolytic and metabolic genes validated the microarray results (Fig. 4D and Fig. S4). According to previous chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) data (Chicas et al., 2010), RB enrichment occurred in association with 36% (109/307) of the metabolic genes in Cluster 20 (Fig. S5 and Table S4), suggesting that both direct and indirect actions of RB are involved in upregulation of a set of metabolic genes. Promoter sequence analysis of RB target genes identified several potential transcription factors (Table S5), some of which are known to cooperate with RB in transcriptional activation (Talluri & Dick, 2012). For example, SP1 has been shown to physically interact with RB and stimulate dihydrofolate reductase gene expression in CHO-K1 cells (Noe et al., 1998). We also identified putative binding sites for CCAAT/enhancer-binding protein beta (C/EBPB), which is known to cooperate with RB in the activation of transcription (Chen et al., 1996). Among these genes, phosphofructokinase, muscle (PFKM) and aldolase C, fructose-bisphosphate (ALDOC) are involved in the production of fructose 1,6-diphosphate and dihydroxyacetone phosphate, respectively, which were significantly reduced by RB-KD (Fig. 2B, PFK and ALDO). We re-evaluated the previously published gene expression profiles of human SAOS-2 cells in which RB had been reintroduced into a RB-/- background (Lopez-Bigas *et al.*, 2008). This data set indicated that the RB reintroduction increased mRNAs of metabolic genes shown in Fig. 4D, while it decreased the mRNA levels of cell cycle genes such as *MCM3* and *MCM5* (Fig. S6). This suggests a conserved role of RB in the upregulation of metabolic genes in different cellular contexts.

Finally, we performed a knockdown of these RB target genes. The loss of glycolytic genes (*PFKM* and *ALDOC*) resulted in decrease in glycolytic activity (ECAR) and mitochondrial OXPHOS (OCR) in OIS cells (Fig. 5). PFKM-KD reduced glycolytic activity more significantly than ALDOC-KD, possibly resulting in the observed effect on downstream OXPHOS capacity. These data suggest that PFKM rather than ALDOC plays an important role in the metabolic remodeling of OIS cells. In addition, we examined the effect of the gene knockdown on the cellular level of dihydroxyacetone phosphate (DHAP), which is generated by aldolases. RB-KD or ALDOC-KD expectedly showed a decrease in the DHAP content in OIS cells, while PFKM-KD was less effective (Fig. S7). This data may suggest that PFKM has multiple effects on the glycolytic pathway. Indeed, fructose 1,6-diphosphate that is generated by PFKM is known to



Fig. 2 RB-dependent metabolic remodeling in OIS cells. (A) Heat map depicts the relative abundance of 103 metabolites. Metabolome (CE-TOFMS/ QqQMS) analyses were performed using three replicates for each cell condition. The color coding indicates the fold change. (B) Metabolites involved in the alvcolvtic pathway. Diagram of glycolytic pathway is shown (left). Statistical analysis was performed using Welch's t-test (*P < 0.05; ***P* < 0.01; ****P* < 0.001). 1,3bisphosphoglycerate was not detected in this analysis. Abbreviations: GLUT, glucose transporter: HK, hexokinase: GPL glucose-6-phosphate isomerase; PFK, phosphofructokinase: ALDO, aldolase: TPL triose phosphate isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; ENO, enolase; PK, pyruvate kinase; LDH, lactate dehydrogenase.

stimulate formation of highly active tetrameric pyruvate kinase M2 (PKM2), thereby promoting the glycolytic pathway (Mazurek, 2011). Collectively, RB appears to mediate OIS-associated metabolic remodeling at least in part through the upregulation of glycolytic genes. Additionally, throughout this study, we observed that RB was present exclusively in the nuclei but not the cytoplasm of IMR90 and OIS cells (data not shown).

It has been reported that fatty acid oxidation contributes to the increased OXPHOS activity in OIS cells (Quijano *et al.*, 2012). Consistently, by treating with etomoxir, a CPT-1 inhibitor, the enhancement of OCR was reduced in OIS cells, compared with the growing (Fig. S8A). Moreover, OCR was increased by the exogenously added free-fatty acid palmitate in CtrI-KD OIS but not in RB-KD OIS cells (Fig. S8B), suggesting that RB is involved in the regulation of fatty acid oxidation in OIS cells. Thus, our result, together with the previous reports (Quijano *et al.*, 2012; Kaplon *et al.*, 2013), indicates that both glycolytic and fatty acid oxidation pathways contribute to maintaining the increased OXPHOS capacity in OIS cells.

Discussion

In this study, we report on the RB mediation of metabolic remodeling in OIS cells. Based on live metabolic monitoring, and metabolome and gene expression analyses, our findings indicate that RB upregulates a series of glycolytic genes, resulting in increased glycolysis and subsequent mitochondrial OXPHOS activities in OIS cells. Thus, OIS cells have activated metabolic flow, in comparison with other cell states.

RB has been found to transcriptionally downregulate some metabolic genes as well as cell cycle genes (Hsieh *et al.*, 2008; Blanchet *et al.*, 2011; Reynolds *et al.*, 2014). For example, the glutamine transporter *SLC1A5* was reported to be a direct target of RB transcriptional repression in mouse embryonic fibroblast cells (Reynolds *et al.*, 2014). By contrast, our study indicated that RB upregulates glycolytic genes and establishes high activities of glycolytic and mitochondrial OXPHOS pathways in OIS cells (Fig. 6). Although the degree of RB-mediated

transcriptional activation was found to be relatively weak (Fig. 4C,D), the RB-dependent upregulation of multiple metabolic genes may synergistically support a metabolically activated phenotype in OIS cells (Fig. 4D and Table S3). Considering that mRNA levels do not always correlate with protein levels, further study may be necessary to address whether the increased mRNAs from metabolic genes are linked to the control of enzymatic activities. A previous study showed that upregulation of the pyruvate dehydrogenase phosphatase 2 gene (PDP2) led to enzymatic activation of pyruvate dehydrogenase (PDH), which catalyzes the conversion of pyruvate into acetyl coenzyme A, and thereby promotes a flux from glycolysis to the TCA cycle in OIS cells (Kaplon et al., 2013). However, details of the upstream pathways regulating PDP2 levels are currently unknown. Interestingly, the PDP2 promoter was bound by RB (Table S4), suggesting that RB participates in the regulation of the PDP2-PDH axis. Thus, RB can contribute to the activation of multiple metabolic pathways. Indeed, the OXPHOS gene set also appears to be upregulated in an RB-dependent manner (Table S2.). Our data strongly suggest that RB regulates a set of metabolic genes at the transcriptional level. However, it is also possible that loss of RB resulted in the stabilization of target mRNAs via unknown mechanisms, which could be a cause of the increased mRNA level.

What is the role of high metabolic potentials in OIS cells? Oncogene signaling is thought to induce metabolic remodeling to support the rapid proliferation and survival of transformed cells. For instance, it has been shown that activation of the K-Ras (Kirsten rat sarcoma viral oncogene homolog) induces the transcriptional upregulation of glycolytic genes (Ying *et al.*, 2012). Cancer cells typically utilize glycolysis to produce ATP while relying to a lesser extent on OXPHOS, which is known as the Warburg effect (Warburg, 1956; Vander Heiden *et al.*, 2009). Considering that OXPHOS produces reactive oxygen species (ROS) (Orrenius *et al.*, 2007), a potential source of cellular damage, the suppression of mitochondrial OXPHOS in cancer cells could be advantageous for survival. Thus, the high glycolytic rates induced by oncogenic activation are not directly linked to OXPHOS capacity in cancer cells. Conversely,



Fig. 3 OIS cells enhance RB-dependent glycolytic properties. (A) Extracellular acidification rate (ECAR) in growing and OIS cells. ECAR was measured as the glycolytic activity using the extracellular flux analyzer (normalized to cell number). Real-time monitoring of ECAR was performed under glucose starvation and readdition (25 mM), completed by adding 2-deoxy-D-glucose (2-DG), a glycolytic inhibitor, at the indicated time points. Values are means \pm SE of at least three technical replicates at each time point. Data are representative of two independent experiments. (B) Effect of RB-KD on glucose uptake in OIS cells. Glucose incorporation rate was determined by flow cytometry using 2-NBDG, a fluorescent glucose analog, in growing, Ctrl-KD OIS, and RB-KD OIS cells. Cells that were untreated with 2-NBDG were used as a negative control. From the histograms of biological triplicate samples (left), mean fluorescence intensities were calculated and shown in the right panel (means \pm SD). Statistical analysis was performed using Welch's *t*-test (***P* < 0.01; ****P* < 0.001).

glycolytic activation in normal cells with an intact mitochondrial function could stimulate downstream OXPHOS and ROS production. Because OISinducing cells are likely to maintain intact mitochondrial potentials, the resulting activation of the energy production by RB may have roles in the initiation and maintenance of cellular senescence (Fig. 6).

Senescence-associated heterochromatin foci (SAHF) are formed by the spatial repositioning of the genome and is correlated with repressive marks such as trimethylated histone H3 on lysine 9 (H3K9me3) and H3K27me3 (Chandra et al., 2012). Although the involvement of epigenetic marks in the OIS state remains poorly understood, alterations in the distribution of histone modifications were previously observed in OIS cells (Chicas et al., 2012; Shah et al., 2013). Recently, there has been increasing evidence of cross talk between the cellular metabolism and epigenome through cellular metabolites (Hino et al., 2013). This is supported by the fact that many epigenetic modifiers utilize metabolites as cofactors or substrates for their enzymatic reactions. Therefore, the levels of cellular metabolites are likely to influence the activity of modifying enzymes at local and whole genomic regions. Indeed, α -KG, an intermediate of the TCA cycle, is required for oxidative lysine demethylation by the Jumonji C domain-containing histone demethylases. In this study, we found that the observed increase in α-KG was RB-dependent in OIS cells (Fig. S3). Additionally, Jumonji/ARID domain-containing protein 1A (JARID1A) and JARID1B, in cooperation with RB, are required for global H3K4me3 demethylation and the silencing of cell cycle gene expression in OIS cells (Chicas *et al.*, 2012). Collectively, RB may therefore coregulate the α -KG increase and H3K4me3 demethylation by JARID1A/1B proteins in the initiation and maintenance of a senescent state.

Finally, we discuss the relationship between cellular metabolism and cell cycle progression in OIS cells. It has been reported that the oscillation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 levels is mediated by targeted degradation by the ubiquitin ligase anaphase-Skp1–Cullin1–F-box complex/cyclosome and promoting complex, together with an increase in lactate production during late G1 phase (Colombo et al., 2011; Tudzarova et al., 2011), suggesting that the cell cycle condition affects metabolism. On the other hand, our present study showed that RB-KD completely reduced mitochondrial OXPHOS activity to the levels seen in growing cells (Fig. 1E) and partially rescued OIS-associated cell cycle arrest (Fig. S1E). Because some metabolic genes are direct targets of RB (Fig. S5 and Table S4), we assumed that OIS-associated metabolic remodeling is not simply a consequence of cell cycle arrest. For future studies, it would be of great interest to determine whether RB-mediated upregulation of metabolic genes occurs in senescent cells in vivo. Enzymes involved in cancerspecific metabolism are potential therapeutic targets, and some inhibitors of these enzymes have been successful in clinical trials (Cheong et al., 2012). Thus, the RB-mediated metabolic remodeling pathway described here could represent a valuable marker and therapeutic target for the prevention of aging-related diseases.

Experimental procedures

Cell culture

IMR90 cells expressing 4-OHT-inducible ER:Ras (H-*ras*V12) were maintained in Dulbecco's modified Eagle's minimal essential medium F12 (045-30665, Wako, Osaka, Japan), supplemented with 10% (v/v) heatinactivated fetal bovine serum (Young *et al.*, 2009). To induce OIS, the cells were treated with 100 nM 4-OHT for 6 days as described previously (Hirosue *et al.*, 2012). IMR90 cells which arrested their growth after 8– 10 weeks of culture were used as RS cells. The following siRNAs were transfected using RNAiMax (Life Technologies, Carlsbad, CA, USA): *siRB1* (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-44273A [designated as #1], B [#2], and C [#3]), *siPFKM* (Life Technologies, *Silencer Select*, 10370), *siALDOC* (Life Technologies, Silencer Select, s1263), and the control siCon (siRNA targeted to luciferase GL3) (Hino *et al.*, 2012). For RB-KD, a mixture of three *siRB1* (A, B, and C) was used at a concentration of 10 nm unless otherwise indicated.

Reverse transcription-PCR

Total cellular RNA was isolated from cells using the RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. cDNA was synthesized with the ReverTra Ace® qPCR RT Master Mix (Toyobo, Osaka, Japan), and quantitative reverse transcription (RT)–PCR performed by the SYBR green method using Thunderbird reagents (Toyobo) and an ABI 7300 Sequence Detector (Applied Biosciences, Foster City, CA, USA). The primer sets used in this study are given in Table S6.

Microarray analysis

Total cellular RNA from two independent experiments was reversetranscribed and hybridized to the Affymetrix U133 Plus 2.0 microarray,



as described previously (Hino *et al.*, 2012). Gene set enrichment analysis was performed using GSEA ver. 2.0 software provided by the Broad Institute of MIT and Harvard (http://www.broadinstitute.org/gsea/) (Subramanian *et al.*, 2005). K-means clustering with the Euclidean distance was performed using MeV 4.8.1 (Saeed *et al.*, 2003), and GO term analysis was carried out with the DAVID functional annotation tool (Dennis *et al.*, 2003). RB enrichment in association with Cluster 20 genes (\pm 2 kb from the transcription start site) was determined using PAVIS (Huang *et al.*, 2013), based on previously reported RB ChIP-seq data in OIS IMR90 cells (Chicas *et al.*, 2010).

Immunoblot analysis

Cell lysates with sample buffer (50 mM Tris–HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 6% β-mercaptoethanol, 10% glycerol, 0.05% bromophenol blue) were separated by SDS-polyacrylamide gel electro-phoresis and transferred to nitrocellulose membranes. Anti-RB rabbit polyclonal antibody (554136, Becton Dickinson, Franklin Lakes, NJ, USA)

Fig. 4 RB mediates the upregulation of a set of glycolytic metabolism genes. (A) Gene set enrichment analysis of upregulated genes in OIS cells. In each panel, nominal P-values and false discovery rates (FDRs) are indicated. The 'glycolysis and gluconeogenesis' gene set was ranked as significantly upregulated in Ctrl-KD OIS but not RB-KD OIS cells. (B) Heat map of gene expression data obtained from growing, Ctrl-KD OIS, and RB-KD OIS cells (n = 2 for each condition). The color coding indicates fold change in expression levels (log2-transformed). Genes were categorized into 20 clusters based on Kmeans clustering. (C) Expression patterns of 1748 genes in Cluster 20. The pink line represents the average of Cluster 20 genes. The y-axis is in log2 scale. (D) RT-PCR analysis of metabolic genes in Cluster 20 in growing, Ctrl-KD OIS, and RB-KD OIS cells. Data are shown as means + SD of three independent experiments. Statistical analysis was performed using Welch's t-test (*P < 0.05; **P < 0.01). Abbreviations: H6PD, hexose-6-phosphate dehydrogenase; PFKM, phosphofructokinase, muscle; HK1, hexokinase 1; ALDOC, aldolase C, fructosebisphosphate; SDHB, succinate dehydrogenase complex, subunit B; EGLN2, Egl-9 family hypoxia-inducible factor 2; SCO2, SCO2 cytochrome c oxidase assembly protein; FLAD1, flavin adenine dinucleotide synthetase 1.

diluted 1:500 and anti- β -tubulin mouse monoclonal antibody (T4026, Sigma, St. Louis, MO, USA) were used as primary antibodies.

Metabolome analysis

Metabolome analysis was performed at Human Metabolome Technologies (HMT, Tsuruoka, Japan, http://humanmetabolome.com). In brief, cells (growing IMR90, Ctrl-KD OIS, and RB-KD OIS) were washed with 5% mannitol solution, and cellular metabolites were extracted using methanol containing HMT Internal Standard Solution 1 at room temperature. Metabolome analysis was performed by CE-TOFMS/QqQMS. Metabolite peaks were quantified and normalized according to the cell number.

Measurement of dihydroxyacetone phosphate

Dihydroxyacetone phosphate content was determined using PicoProbeTM Dihydroxyacetone Phosphate Fluorometric Assay Kit (BioVision, Milpitas, CA, USA), according to the manufacturer's instructions.



Fig. 5 Effect of glycolytic gene knockdown on glycolytic and mitochondrial OXPHOS activities. (A, B) The RB-targeted glycolytic genes *PFKM* and *ALDOC* were depleted using specific siRNAs in OIS cells (left). Data are shown as means \pm SD of three independent experiments. ECAR and OCR were measured as described in Figs 3A and 1A, respectively (right). Statistical analysis was performed using Welch's *t*-test (**P* < 0.05; ***P* < 0.01).



Fig. 6 Schematic model for RB-mediated activation of both glycolysis and mitochondrial OXPHOS in OIS cells. In response to oncogenic signals, RB either directly or indirectly upregulates the mRNA levels of target genes such as glycolytic genes. Glycolytic stimulation promotes a metabolite flux into the TCA cycle, leading to OIS-driven mitochondrial OXPHOS activation. Consequently, OIS cells are metabolically activated under growth arrest, compared with normal cells and proliferative cancer cells.

Assessment of glucose incorporation rate

The fluorescent glucose analog 2-NBDG (Peptide Institute Inc., Osaka, Japan) was used to monitor the glucose incorporation rate. Cells cultured in medium containing 100 μ M 2-NBDG for 2 h were collected using the Accumax reagent (Innovative Cell Technologies, San Diego,

CA, USA), and fluorescence was measured by fluorescence-activated cell sorting with a Canto flow cytometer (Becton Dickinson).

Real-time measurement of glycolytic and OXPHOS activities

Real-time monitoring of cellular metabolic activities was performed using an XF24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA, USA), according to the manufacturer's instructions. Control and siRNA-treated cells were cultured on the assay culture plate for 24 h before the assay. Before loading the assay culture plate on to the XF24 extracellular flux analyzer, cells were cultured in unbuffered DMEM (DMEM with 25 mm glucose, 1 mm sodium pyruvate, 2 mm L-glutamate, pH 7.4) and incubated in a non-CO₂ incubator for 1 h at 37 °C. Maximum OXPHOS capacity was determined as previously reported with some modifications (Hino et al., 2012). In brief, during the real-time measurement, inhibitors of respiratory chain components were serially added to the culture: the complex V inhibitor oligomycin (1 μ M), the respiratory uncoupler FCCP (1.5 µm), and the complex I/III inhibitors rotenone (1 µm) and antimycin A (1 µm). After each addition, the OCR was measured four times. The addition of FCCP accelerates oxygen consumption to a maximum level, whereas complex I inhibitors completely abolish mitochondrial respiration. Thus, the difference in OCR between FCCP- and rotenone/antimycin-treated states indicates the maximum OXPHOS capacity. To test for glycolytic activities, cells were starved in glucose-free medium for 3 h, after which glucose was reintroduced (25 mm). Cells were then treated with 100 mm 2-DG, a glycolytic inhibitor. Real-time OCR and ECAR data in all the figures are representative of at least two independent biological replicates. Values are means \pm SE of at least three technical replicates at each time point. For technical replicates, Ras induction and siRNA treatment were

performed using at least three independent cultures for each experiment. Briefly, control OIS and knockdown cells from the same original culture were pooled and plated on three-to-six-well SeaHorse microplate for the measurement. To examine the contribution of fatty acid oxidation to OCR in OIS cells, cells were treated with 100 μ M etomoxir, a CPT1 inhibitor. To prepare a fatty acid complex that can be incorporated into cells, palmitate was conjugated with BSA in a 6 to 1 molar ratio as described previously (Zhang *et al.*, 2012). Palmitate-BSA conjugate (100 μ M) was added to the cells just prior to the OCR measurement (t = 0).

Acknowledgments

We thank the members of our laboratory and Dr. Ben Pope for helpful comments and discussions.

Author contributions

S. T. and M. Nakao designed the research and wrote the paper; S. T., H. T., T. I., A.S., and Y. N. carried out experiments and analyzed data; S. H. supported metabolic analysis; and M. Narita provided the cells.

Funding info

This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (M. Nakao and S. T.), the Japan Science and Technology Agency (CREST), the Takeda Science Foundation (M. Nakao), by the Program for Leading Graduate Schools 'HIGO (Health life science: Interdisciplinary and Glocal Oriented) Program', Kumamoto University (M. Nakao and S. T.), and by the University of Cambridge, Cancer Research UK, Hutchison Whampoa (M. Narita).

Conflict of interest

The authors declare no conflict of interest.

References

- Ben-Porath I, Weinberg RA (2005) The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37, 961–976.
- Blanchet E, Annicotte JS, Lagarrigue S, Aguilar V, Clape C, Chavey C, Fritz V, Casas F, Apparailly F, Auwerx J, Fajas L (2011) E2F transcription factor-1 regulates oxidative metabolism. *Nat. Cell Biol.* **13**, 1146–1152.
- Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. *Nature* **391**, 597–601.
- Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. *Nat. Rev. Mol. Cell Biol.* **8**, 729–740.
- Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, Ahmed K, Samarajiwa SA, Salama R, Carroll T, Stark R, Janky R, Narita M, Xue L, Chicas A, Nunez S, Janknecht R, Hayashi-Takanaka Y, Wilson MD, Marshall A, Odom DT, Babu MM, Bazett-Jones DP, Tavare S, Edwards PA, Lowe SW, Kimura H, Gilbert DM, Narita M (2012) Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. *Mol. Cell* **47**, 203–214.
- Chen PL, Riley DJ, Chen Y, Lee WH (1996) Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/ EBPs. *Genes Dev.* **10**, 2794–2804.
- Cheong H, Lu C, Lindsten T, Thompson CB (2012) Therapeutic targets in cancer cell metabolism and autophagy. *Nat. Biotechnol.* **30**, 671–678.
- Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW (2010) Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cancer Cell* **17**, 376–387.

- Chicas A, Kapoor A, Wang X, Aksoy O, Evertts AG, Zhang MQ, Garcia BA, Bernstein E, Lowe SW (2012) H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc. Natl Acad. Sci. USA 109, 8971–8976.
- Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. *Nat. Rev. Cancer* **10**, 51–57.
- Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, Tudzarova S, Moncada S (2011) Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. *Proc. Natl Acad. Sci. USA* **108**, 21069–21074.
- Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol.* **4**, P3.
- Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfurst B, Walenta S, Mueller-Klieser W, Graler M, Hummel M, Keller U, Buck AK, Dorken B, Willmitzer L, Reimann M, Kempa S, Lee S, Schmitt CA (2013) Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. *Nature* **501**, 421–425.
- Hino S, Sakamoto A, Nagaoka K, Anan K, Wang Y, Mimasu S, Umehara T, Yokoyama S, Kosai K, Nakao M (2012) FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. *Nat. Commun.* **3**, 758.
- Hino S, Nagaoka K, Nakao M (2013) Metabolism-epigenome crosstalk in physiology and diseases. J. Hum. Genet. **58**, 410–415.
- Hirosue A, Ishihara K, Tokunaga K, Watanabe T, Saitoh N, Nakamoto M, Chandra T, Narita M, Shinohara M, Nakao M (2012) Quantitative assessment of higherorder chromatin structure of the INK4/ARF locus in human senescent cells. *Aging Cell* **11**, 553–556.
- Hsieh MC, Das D, Sambandam N, Zhang MQ, Nahle Z (2008) Regulation of the PDK4 isozyme by the Rb-E2F1 complex. J. Biol. Chem. 283, 27410–27417.
- Huang W, Loganantharaj R, Schroeder B, Fargo D, Li L (2013) PAVIS: a tool for peak annotation and visualization. *Bioinformatics* 29, 3097–3099.
- Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E, Peeper DS (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. *Nature* **498**, 109–112.
- Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev. 24, 2463–2479.
- Lopez-Bigas N, Kisiel TA, Dewaal DC, Holmes KB, Volkert TL, Gupta S, Love J, Murray HL, Young RA, Benevolenskaya EV (2008) Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. *Mol. Cell* **31**, 520–530.
- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153, 1194–1217.
- Luo RX, Postigo AA, Dean DC (1998) Rb interacts with histone deacetylase to repress transcription. *Cell* **92**, 463–473.
- Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. *Nature* **391**, 601–605.
- Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969–980.
- Munoz-Espin D, Serrano M (2014) Cellular senescence: from physiology to pathology. *Nat. Rev. Mol. Cell Biol.* **15**, 482–496.
- Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* **113**, 703–716.
- Noe V, Alemany C, Chasin LA, Ciudad CJ (1998) Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter. *Oncogene* **16**, 1931–1938.
- Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 47, 143–183.
- Perez-Mancera PA, Young AR, Narita M (2014) Inside and out: the activities of senescence in cancer. Nat. Rev. Cancer 14, 547–558.
- Quijano C, Cao L, Fergusson MM, Romero H, Liu J, Gutkind S, Rovira II, Mohney RP, Karoly ED, Finkel T (2012) Oncogene-induced senescence results in marked metabolic and bioenergetic alterations. *Cell Cycle* **11**, 1383–1392.
- Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, Hill BG, Dean DC, Clem BF (2014) Control of glutamine metabolism by the tumor suppressor Rb. *Oncogene* **33**, 556–566.
- Rodier F, Campisi J (2011) Four faces of cellular senescence. J. Cell Biol. **192**, 547–556.
- Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J (2003)

TM4: a free, open-source system for microarray data management and analysis. *Biotechniques* **34**, 374–378.

Salama R, Sadaie M, Hoare M, Narita M (2014) Cellular senescence and its effector programs. Genes Dev. 28, 99–114.

- Shah PP, Donahue G, Otte GL, Capell BC, Nelson DM, Cao K, Aggarwala V, Cruickshanks HA, Rai TS, McBryan T, Gregory BD, Adams PD, Berger SL (2013) Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. *Genes Dev.* 27, 1787–1799.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545– 15550.
- Takahashi C, Sasaki N, Kitajima S (2012) Twists in views on RB functions in cellular signaling, metabolism and stem cells. Cancer Sci. 103, 1182–1188.
- Talluri S, Dick FA (2012) Regulation of transcription and chromatin structure by pRB: here, there and everywhere. *Cell Cycle* **11**, 3189–3198.
- Tudzarova S, Colombo SL, Stoeber K, Carcamo S, Williams GH, Moncada S (2011) Two ubiquitin ligases, APC/C-Cdh1 and SKP1-CUL1-F (SCF)-beta-TrCP, sequentially regulate glycolysis during the cell cycle. *Proc. Natl Acad. Sci. USA* **108**, 5278–5283.
- Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **324**, 1029–1033.
- Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley C, Ramalho-Santos J, Van HB, Schatten G (2011) Energy metabolism in human pluripotent stem cells and their differentiated counterparts. *PLoS ONE* **6**, e20914.

Warburg O (1956) On the origin of cancer cells. Science 123, 309–314.

- Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD (2007) Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1amediated formation of senescence-associated heterochromatin foci. *Mol. Cell. Biol.* 27, 2452–2465.
- Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* **149**, 656–670.
- Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavare S, Arakawa S, Shimizu S, Watt FM, Narita M (2009) Autophagy mediates the mitotic senescence transition. *Genes Dev.* 23, 798–803.
- Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, Imam SS, Vergnes L, Malone CS, Koehler CM, Teitell MA (2012) Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. *Nat. Protoc.* 7, 1068–1085.

Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, Blau CA, Horwitz MS, Hockenbery D, Ware C, Ruohola-Baker H (2012) HIF1alpha induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/ hESC transition. *EMBO J.* **31**, 2103–2116.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

Fig. S1 Experimental design and the effect of RB-KD on OIS cells.

Fig. S2 Mitochondrial OXPHOS capacity under indicated experimental conditions.

Fig. S3 Effect of RB-KD on metabolic products in OIS cells.

Fig. 54 Effect of RB-KD using individual siRNAs on metabolic gene expression.

Fig. S5 RB enrichment in association with metabolic genes in Cluster 20.

 $\ensuremath{\textit{Fig. S6}}$ Results of metabolic gene expression from the previously published dataset.

Fig. S7 Effect of glycolytic gene knockdown on cellular dihydroxyacetone phosphate content.

Fig. S8 Contribution of fatty acid oxidation on mitochondrial OXPHOS activity in OIS cells.

Table S1 Summary of metabolite profiling in growing (IMR90), Ctrl-KD OIS, and RB-KD OIS cells.

 Table S2
 Gene set enrichment analysis of pathways upregulated in Ctrl-KD

 OIS and RB-KD OIS, compared with growing IMR90 cells.
 Cells.

Table S3 List of metabolic genes in Cluster 20.

Table S4 Summary of RB enrichment in association with metabolic genes in Cluster 20.

 Table S5 Putative transcription factor binding sites in metabolic gene promoters.

Table S6 Primers used in this study.